Has John Henegan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,163,368 in general payments to John Henegan, MD across 776 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Henegan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Henegan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Henegan, MD

Hematology & Oncology · Jackson, MSNPI 1114188471

Payments from drug & device makers

$1,163,368in general payments, 2019–2025

Across 776 payments — averaging $1499.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$761K
Merck$207K
Astrazeneca UK Limited$80K
Pfizer$32K
Seagen Inc.$22K
Pharmacyclics LLC, An Abbvie Company$19K
plus $41K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	52	$761,427
Merck	65	$207,443
Astrazeneca UK Limited	4	$79,784
Pfizer	49	$32,044
Seagen Inc.	18	$22,409
Pharmacyclics LLC, An Abbvie Company	3	$18,542
Taiho Oncology, Inc.	3	$9,015
Caris MPI, Inc.	2	$8,595
Sanofi	31	$8,076
Exelixis Inc.	31	$4,669
AVEO Pharmaceuticals, Inc.	5	$1,572
Johnson & Johnson(2 entities)	56	$878
Incyte Corporation	64	$866
AstraZeneca(2 entities)	31	$715
Astellas Pharma US Inc	27	$528
AbbVie	17	$454
Takeda Pharmaceuticals U.S.A., Inc.	23	$444
Amgen	22	$429
Gilead(2 entities)	11	$415
Bristol Myers Squibb	18	$371
Sanofi-aventis U.S. LLC	7	$335
Dendreon Pharmaceuticals LLC	9	$306
E.r. Squibb & Sons, L.L.C.	22	$298
Daiichi Sankyo Inc.	7	$152
Regeneron Healthcare Solutions, Inc.	7	$151
Genentech USA, Inc.	8	$150
Ipsen Biopharmaceuticals, Inc	7	$133
Rigel Pharmaceuticals, Inc.	6	$131
Karyopharm Therapeutics Inc.	7	$127
EMD Serono, Inc.	8	$126
GSK	7	$124
Alnylam Pharmaceuticals Inc.	7	$106
ADC Therapeutics America, Inc.	6	$106
Bayer	6	$106
Beone Medicines USA, Inc.	5	$101
Pharmaessentia USA Corporation	4	$93
Eisai Inc.	5	$92
Beigene USA, Inc.	5	$91
Stemline Therapeutics Inc.	4	$89
Blueprint Medicines Corporation	3	$87
Coherus Oncology, Inc.	4	$84
Springworks Therapeutics, Inc.	5	$82
Emmaus Medical, Inc.	4	$74
Verastem, Inc.	5	$69
Boehringer Ingelheim	4	$69
Sobi, Inc	3	$67
Adaptive Biotechnologies Corporation	3	$64
Servier Pharmaceuticals LLC	4	$62
Array Biopharma Inc	4	$60
Immunocore Limited	2	$58
Jazz Pharmaceuticals Inc.	3	$57
Secura Bio, Inc.	5	$54
EUSA Pharma (US) LLC	3	$52
Geron Corporation	2	$52
Dova Pharmaceuticals	3	$51
Recordati_rare_diseases_inc.	3	$49
Morphosys, US Inc.	3	$49
Novo Nordisk	2	$46
Lilly USA, LLC	3	$45
Sanofi US Services Inc.	2	$40

How this compares

$1,163,368 in reported general payments places this provider in the 90th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi →

Medicare billing

Part B allowed, 2024

$113,403

Medicare patients

313

Services billed

1,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Jackson

Justin BakerJackson$2.1M
Carter MilnerJackson$261K
Barbara CraftJackson$135K
Guangzhi QuJackson$78K
Bobby WilkersonJackson$28K
Grace ShumakerJackson$10K
Katherine ThielJackson$2K
John HromHattiesburg$10M
Solly ChedidPascagoula$1.7M
Andrew KellumTupelo$171K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →